Provided by Tiger Trade Technology Pte. Ltd.

Valneva SE

6.96
+0.14002.05%
Post-market: 6.960.00000.00%16:10 EDT
Volume:21.59K
Turnover:150.20K
Market Cap:660.40M
PE:-3.45
High:7.06
Open:6.77
Low:6.71
Close:6.82
52wk High:12.23
52wk Low:4.75
Shares:94.89M
Float Shares:78.63M
Volume Ratio:0.03
T/O Rate:0.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.0180
EPS(LYR):-1.6084
ROE:-117.85%
ROA:-16.68%
PB:6.97
PE(LYR):-4.33

Loading ...

Valneva (VALN) Gets a Buy from H.C. Wainwright

TIPRANKS
·
May 27

Valneva SE reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 13

Valneva Q1 EPS $(0.42) Misses $(0.21) Estimate, Sales $36.189M Miss $46.270M Estimate

Benzinga Earnings
·
May 13

Press Release: Valneva Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Dow Jones
·
May 13

Valneva SE expected to post a loss of 11 cents a share - Earnings Preview

Reuters
·
May 11

Valneva Sets May 13 Date to Present First-Quarter 2026 Results

TIPRANKS
·
May 06

Valneva Raises Up to €84 Million via Private Placement Tied to Lyme Vaccine Milestone

TIPRANKS
·
May 01

Goldman Sachs Downgrades Valneva to Sell From Neutral, Adjusts Price Target to $4.90 From $7.50

MT Newswires Live
·
Apr 22

Federal Court Reportedly Halts Kennedy's Vaccine Panel, Putting COVID, Flu And RSV Shots At Risk

Benzinga_recent_news
·
Apr 21

Valneva Showcases Chikungunya Vaccine Progress at World Vaccine Congress in Washington

TIPRANKS
·
Mar 27

Jefferies says Valneva stock weakness presents buying opportunity

TIPRANKS
·
Mar 24

Valneva Down Over 36%, on Pace for Largest Percent Decrease Since September 2021 -- Data Talk

Dow Jones
·
Mar 23

Top Premarket Decliners

MT Newswires Live
·
Mar 23

Pfizer, Valneva announce ‘positive’ results from Phase 3 VALOR trial

TIPRANKS
·
Mar 23

Pfizer: Co & Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 Valor Trial

THOMSON REUTERS
·
Mar 23

Pfizer-Valneva Lyme disease shot shows more than 70% efficacy in late-stage trial

Reuters
·
Mar 23

Guggenheim Reaffirms Their Buy Rating on Valneva (VALN)

TIPRANKS
·
Mar 19

Analysts Offer Insights on Healthcare Companies: Stoke Therapeutics (STOK), Valneva (VALN) and Protagonist Therapeutics (PTGX)

TIPRANKS
·
Mar 19

Goldman Sachs Reaffirms Their Hold Rating on Valneva (VALN)

TIPRANKS
·
Mar 19

Valneva Licenses C. Difficile Antigen Technology to Elaris

MT Newswires Live
·
Mar 18